Your Search Returned 164 tagged news reports
Public companies are required to release information that's material to their stock price. While it's easy to ignore this nuance since most investors can't invest in private companies, that's not a wise move. As Fool contributor Brian Orelli and
announced that it was on recalling its over-the-counter obesity drug, Alli, in the U.S. and Puerto Rico because it appears that some packages were tampered with. The drug remains on the shelf in Europe, where there doesn't seem to be a problem.
Friday after announcing earnings on Thursday night that included a rather paltry $2.3 million in revenue from sales of its obesity drug Belviq...We've known about the fourth-quarter sales since Arena's marketing partner Eisai issued earnings earlier
In recent months, analysts have been slightly less enthusiastic about Arena earnings, cutting their fourth-quarter estimates in half. But they've held their full-year 2014 projections steady, and the stock has actually jumped 28% since mid-November.
The stock had earlier closed up 4.4% in anticipation of better earnings and revenues than had been expected by analysts, and the company had delivered but only on the back of a one-time gain...He also cut BofA's target price for Vivus to $6, from a
CEO Seth Fischer started off by announcing that the company has modified the design of Qsymia's postmarketing study in the U.S. to create a potential pathway to approval in Europe. As a refresher, Qsymia's application in Europe was rejected last year
for Stendra (marketed in the European Union as Spedra), a treatment for erectile dysfunction. The remaining $9.2 million in revenue came from product sales, including $7.7 million from chronic weight management drug Qsymia, and $1.5 million from
The stock has kept sliding, losing more than 30% of its value since mid-November...In response, the company said it would cut 20 workers, representing about a sixth of its workforce, in order to help reduce overhead costs...Arena's Belviq sales for
Microsoft made headlines for the announcement that Steve Ballmer will step down, and J.C...But there were also three health-care stocks that made news for their changes at the top. Of course, management changes are part of the business world. All
Sanofi to commercialize avanafil on an exclusive basis in Africa, the Middle East, Turkey, and the Commonwealth of Independent States (CIS) including Russia. Sanofi will be responsible for obtaining regulatory approval in its territories...Menarini